A Translational Story Panel Discussion
A powerful driver for scientist is to make a meaningful impact on society. Many of the discoveries that improved and will improve our lives and health have come from basic university research. However, moving out of the academic lab into the market is generally not the focus of academia. Industry expertise provides a conduit for translational for startups and entrepreneurs to help their ideas and research have a meaningful impact on the world. But how does this all work?
We asked a group of professionals from academia and the life science industry to share their experience and advise us on how to successfully translate research to market solutions and explain how different academic systems within and across borders handle this process. Join us to learn more about the challenges and opportunities of moving your science out of the lab and into the market.
Canadian Start-Up Showcase: Entos Pharmaceutical
Follow us on LinkedIn and Twitter and for more information, please visit www.cels-sfo.com
Jill de Grood | Director, W21C Research and Innovation Centre read bio»
John Lewis | CEO, Entos Pharmaceuticals | Frank and Carla Sojonky Chair in Prostate Cancer Research, University of Alberta read bio»
Daria Mochly-Rosen | The George D. Smith Professor In Translational Medicine, Chemical and Systems Biology, Stanford University read bio»
Stephanie Robertson | Sr. Director, Consumer Science Innovation, Johnson & Johnson Innovation, California read bio»
3:00 PM | Registration and networking
3:30 PM | Presentation, John Lewis, Entos Pharmaceuticals
3:45 PM | Presentation, Jill de Grood, W21C Research and Innovation Centre
4:00 PM | Translational Panel and Q&A
5:00 PM | Networking Session
6:00 PM | Program Close
NOTE: Virtual Guests - The event will be available in a webinar format with Q&A questions submitted by chat mode
Have questions about CELS COHORT Mentor Program – Contact CELS - SFO
JLABS @ SSF
329 Oyster Point Blvd - 3rd Floor
South San Francisco, California
Jill de Grood | Director, W21C Research and Innovation Centre
Jill de Grood completed her Masters degree in Sociology at the University of Calgary. Her thesis project examined factors impacting lawyer's physical and mental health. She completed a Certificate in Professional Management in 2015 and recently completed the University of Calgary's ULead Experiential Leadership Program. She has been in an evolving leadership role with W21C for eight years, with involvement in numerous industry partner projects in areas such as technology assessment, infection prevention and control, as well as examining the effectiveness of health care innovations and their impact on patient care. Jill is a published author with eight journal publications along with two knowledge translation pieces. She is currently the Director of W21C, bringing a strategic perspective to the W21C on the challenges and opportunities the program faces. She works with the W21C team, external stakeholders and partners to build on the success of the W21C program over the past 13 years.
John Lewis | CEO, Entos Pharmaceuticals | Frank and Carla Sojonky Chair in Prostate Cancer Research, University of Alberta
John is an academic scientist and serial entrepreneur. He holds the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta and chairs the Alberta Prostate Cancer Research Initiative.
John's research interests lie in the areas of nanotechnology and imaging as they relate to the development of novel treatments for chronic diseases such as aging and cancer. Because no man dies of prostate cancer that stays in his prostate, the group is study the spread, or metastasis, of cancer using advanced live imaging techniques. The group has used this approach to identify key drivers of metastatic cancer progression, and is leveraging this information to develop novel nanoparticles to block the spread of prostate and other cancers. To accelerate their translation to the clinic, Dr. Lewis has founded several Canadian biotechnology companies, including Entos Pharmaceuticals.
John is founder and CEO of Entos Pharmaceuticals, a biotechnology company focused on the development of next generation nucleic acid-based therapies. Entos's drug delivery technology, Fusogenix, is a platform that enables the formuation of safe and effective formulations for gene therapy, mRNA, miRNA, RNAi and CRISPR. Entos's lead development candidate, a suicide gene therapy for prostate cancer, will enter the clinic in 2018.
Dr. Lewis holds a Ph.D. in biochemistry from the University of Victoria, and completed postdoctoral training at The Scripps Research Institute in La Jolla, CA.
Daria Mochley-Rosen| The George D. Smith Progessor In Translational Medicine, Chemical and Systems Biology, Stanford University
Dr. Daria Mochly-Rosen, Ph.D. is the Co-founder of Mitoconix Bio Ltd. Dr. Mochly-Rosen is the founder and co-director of SPARK, a university-wide program focusing on translational research to benefit patients and society. She co-founded KAI Pharmaceuticals, Inc. in 2002 and served as its Chief Scientific Officer, Scientific Consultant, Chairperson of the Scientific Advisory Board and Director. Dr. Mochly-Rosen is the George D. Smith Professor of Translational Medicine and the Professor and Chair of the Department of Molecular Pharmacology at Stanford University. She was Assistant and Associate Professor at UCSF (1985-1992), until she joined Stanford University, in January 1993. She was the holder of the Reeds-Hodgson endowed chair in Human Biology at Stanford University. Prior to 1993, Dr. Mochly-Rosen spent seven years at the University of California, San Francisco, Department of Neurology. Dr. Mochly-Rosen serves as a Director of ALDEA Pharmaceuticals, Inc. Dr. Mochly-Rosen's research focuses on the rational design of peptides that interfere with protein-protein interactions and their use in the study of intracellular signal transduction in normal and disease states. She has served as a member of several scientific advisory boards and holds nine issued patents with several patents pending. She has been a Director of California Life Sciences Association since February 13, 2017. Dr. Mochly-Rosen has served as a member of peer review committees and leadership committees in academia and is a Fellow in the Council on Basic Cardiovascular Sciences of the American Heart Association and a Founding Fellow of the International Society of Heart Research. She has published over 250 papers and over 30 patents and patent applications and have founded three companies: KAI Pharmaceuticals (2003-2011 when acquired by AMGEN), ALDEA (developed by Aviv Therapeutics, now FORESEE; 2013-) and Mitoconix (2016-). She received her B.Sc. in Life Sciences from Tel Aviv University and her Ph.D. in Chemical Immunology from the Weizmann Institute of Science in Rehovot, Israel. She completed a postdoctoral fellowship in the Department of Biochemistry at University of California, Berkeley.
Stephanie Robertson, PhD. | Sr. Director, Consumer Science Innovation Johnson & Johnson Innovation, California
Stephanie is part of the New Ventures Team at J&J Innovation. As part of her role at J&J Innovation, she works closely with the Janssen Human Microbiome Institute and with J&J Consumer Emerging Sciences to create collaborations with academic experts and biotech companies with a goal of accelerating the translation of microbiome research into breakthrough solutions that promote health. Previously Stephanie was at the University of California, San Francisco UCSF where she helped to establish and grow translational efforts on campus including her role as Program Director for the Sandler Center for Drug Discovery, and for the Grand Multiple Myeloma Translational Initiative. She later took on the role of Director, Strategic Alliances where she led business development and alliance management activities for the campus. Prior to joining UCSF, Stephanie worked for over a decade at Exelixis, Inc, where she held diverse leadership roles including leading a computational biology team and acting as scientific project leader for numerous drug discovery programs in cancer, cardiovascular disease and metabolism as well as managing early oncology clinical programs and alliances for several programmatic collaborations with large pharma.
Stephanie earned an undergraduate degree in chemistry (Honors) at the University of Michigan, Ann Arbor, and a Ph.D. in chemistry at the University of California, Berkeley.